Teva (TEVA) EVP Daniell Richard sells 91,345 shares as RSUs vest

Rhea-AI Filing Summary

Teva Pharmaceutical Industries EVP, Europe Commercial Daniell Richard reported a combination of equity awards, vesting and share sales. On March 4, 2026, he exercised restricted share units into 33,512 and 20,461 ordinary shares and received a new grant of 33,424 restricted share units.

He then sold 91,345 ordinary shares in open-market transactions at weighted average prices of $32.4645 and $32.9474, executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2025. Following these trades, he directly owned 85,755 ordinary shares. The filing notes the sales related to vesting of restricted share units, including shares sold to cover tax withholding obligations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daniell Richard

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Europe Commercial

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/04/2026		M		33,512	A	(2)	156,639	D
Ordinary Shares(1)	03/04/2026		S(3)		33,512(4)	D	$32.4645(5)	123,127	D
Ordinary Shares(1)	03/04/2026		M		20,461	A	(2)	143,588	D
Ordinary Shares(1)	03/04/2026		S(3)		20,461(4)	D	$32.4645(5)	123,127	D
Ordinary Shares(1)	03/04/2026		S(3)		37,372	D	$32.9474(6)	85,755	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/04/2026		M			33,512	(7)	(7)	Ordinary Shares(1)	33,512	$0	0	D
Restricted Share Units	(2)	03/04/2026		M			20,461	(8)	(8)	Ordinary Shares(1)	20,461	$0	40,923	D
Restricted Share Units	(2)	03/04/2026		A		33,424		(9)	(9)	Ordinary Shares(1)	33,424	$0	33,424	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

4. Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.905 to $33.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

7. Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.

8. Restricted share units were granted on March 4, 2024, with 20,461 vested on each of March 4, 2025 and March 4, 2026, 20,461 vesting on March 4, 2027, and 20,462 vesting on March 4, 2028.

9. Restricted share units were granted on March 4, 2026, with 8,356 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030.

	/s/ Dov Bergwerk as attorney-in-fact for Richard Daniell	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Teva (TEVA) executive Daniell Richard report?

He reported exercises of restricted share units into ordinary shares, a new grant of 33,424 restricted share units, and open-market sales of 91,345 ordinary shares. These transactions occurred on March 4, 2026 and involved both equity acquisition and disposition activity.

How many Teva (TEVA) shares did Daniell Richard sell and at what prices?

He sold a total of 91,345 ordinary shares in open-market transactions. Weighted average sale prices were $32.4645 and $32.9474, with detailed trade ranges from $32.095 to $33.30 and from $32.905 to $33.07, as disclosed in the footnotes.

Were Daniell Richard’s Teva (TEVA) share sales under a 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on November 10, 2025. Such plans pre-schedule trades, providing structure for selling shares over time under pre-defined conditions.

How many Teva (TEVA) shares does Daniell Richard own after these transactions?

After the March 4, 2026 transactions, Daniell Richard directly owned 85,755 ordinary shares of Teva. This figure reflects the net result of restricted share unit exercises, a new restricted share unit grant, and the reported open-market share sales.

What restricted share unit grants for Teva (TEVA) does Daniell Richard have outstanding?

He holds restricted share units granted in 2024 and 2026 with scheduled vesting through 2030. Footnotes describe annual vesting tranches of 20,461–20,462 units from 2025–2028, and 8,356 units each year from 2027–2030, each unit tied to one ordinary share or its cash value.

How are Teva (TEVA) restricted share units settled for Daniell Richard?

Each restricted share unit represents a contingent right to receive one ordinary share at settlement, or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. This structure links long-term compensation to Teva’s equity performance.